Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data

BACKGROUND AND OBJECTIVES: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard-of-care first-line (1L) treatment for EGFR mutation-positive advanced/metastatic non-small cell lung cancer. In 2015, osimertinib, a third-generation EGFR-TKI, received US accelerated appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nieva, Jorge, Reckamp, Karen L., Potter, Danielle, Taylor, Aliki, Sun, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392819/
https://www.ncbi.nlm.nih.gov/pubmed/35661118
http://dx.doi.org/10.1007/s40801-022-00302-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392819/
https://www.ncbi.nlm.nih.gov/pubmed/35661118
http://dx.doi.org/10.1007/s40801-022-00302-w

Ejemplares similares